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Summary A population-based case-control study of oral contraceptive use and breast cancer was carried out
among young women (<43 years of age) at Group Health Cooperative of Puget Sound, Seattle, Washington.
Use of oral contraceptives before first pregnancy did not materially differ between cases or controls. The rate
ratio estimate of breast cancer incidence in women who had used oral contraceptives before first pregnancy
compared to those who had not was 0.9 (95% CI =0.4, 2.1). There were no meaningful patterns of
association between breast cancer and duration of use or formulation of oral contraceptive used before first
pregnancy.
There is considerable uncertainty about the relation of oral
contraceptive use before a first pregnancy and the risk of
breast cancer in premenopausal women. Recently,
McPherson et al. (1987) reported a positive association
between oral contraceptive use before a full term pregnancy
and breast cancer. This association was strongest in the
comparison of women who had used oral contraceptives for
more than 4 years with women who had used them for fewer
years. In addition, the association was strongly positive in
women whose oral contraceptive formulation contained
ethinyl oestradiol. In women whose oral contraceptive
formulation contained mestranol there was a negative
association with breast cancer. Two other studies have
shown positive associations between early oral contraceptive
use and breast cancer (Meirick et al., 1986; Pike et al., 1981)
but have not been in accord on the subgroups of users at
elevated risk. A number of other studies (Paul et al., 1986;
Rosenberg et al., 1984; Schlesselman et al., 1988; Cancer
and Steroid Hormone Study, 1986) have not shown any of
the reported effects. In order to provide further information
on this important issue, we have reviewed the results of
interviews of premenopausal women with breast cancer and
of matched controls that were carried out at Group Health
Cooperative of Puget Sound (GHC) for the period 1 July
1975 to 30 December 1983. A report that included some of
the interview data presented here has been previously
presented (Jick et al., 1980). The primary focus in the
current analysis of these data is the relation between the use
of oral contraceptives before first pregnancy and the risk of
breast cancer.
Methods
Group Health Cooperative of Puget Sound is a consumer-
owned cooperative founded in Seattle, Washington in 1945.
As of 1983 the Cooperative had over 300,000 members. The
plan provides virtually complete prepaid medical coverage
for outpatient care, drugs and hospital services. Members,
with some exceptions, are hospitalised at Seattle-area
hospitals maintained by the Cooperative. Around 90% of
the GHC members are caucasian.
During the period covered by this study, information on
all discharges from GHC hospitals was recorded on
computer files by the Commission on Professional and
Hospital Activities - Professional Activity Study (CPHA-
PAS) in Ann Arbor, Michigan. This information includes
patient identification, dates of admission and discharge,
surgical procedures performed and discharge diagnoses.
GHC also maintains and has computerised its own tumour
Correspondence: H. Jick.
Received 16 May 1988, in revised form, 2 February 1989.
registry, which regularly exchanges data with the local
Surveillance, Epidemiology and End Results (SEER) tumour
registry.
Information of prescriptions for all outpatient drugs
(including over-the-counter drugs) filled at any GHC
pharmacy has been available on computer file since July
1975. In previous interview studies of the GHC population,
including over 1,000 women, over 95% stated that they
routinely used GHC pharmacies to obtain their prescriptions
(Jick et al., 1979, 1980).
Cases of breast cancer
In order to include women who are likely to have been of
childbearing age in the early 1960s when oral contraceptives
first became available, we restricted the study to women less
than 43 years of age at the time of diagnosis. Women
beyond age 42 in the study would have had little oppor-
tunity to be exposed to oral contraceptives before their first
pregnancy. We identified 102 women less than 43 years of
age, newly diagnosed as having breast cancer (ICDA Code
174.0), between 1 July 1978 and 31 December 1983, from the
computer files and through the GHC tumour registry.
Seven cases were excluded from the study: two with a
prior history of cancer, two who could not be located, two
for whom permission to interview was denied, and one
whose cancer was diagnosed before joining GHC. A total of
95 cases remained in the study.
Control subjects
The population from which control subjects were selected for
each case consisted of all women of similar age who were
members of the plan on the date of diagnosis of the case and
who had been members of the plan for a similar duration of
time. We obtained a set of controls for each case in a two-
stage process. First, four comparison subjects were selected
from the GHC membership roster for each case, matched on
year of birth within two years and first digit of the medical
history number, which acts as a proxy for date of entry into
the health plan. Since the membership roster comprises all
persons who have been members of the Cooperative, at any
time, the comparison subjects were not all eligible controls,
because they may not have been members of the plan on the
required date of case diagnosis. Those comparison subjects
who had been members on the requisite dates were taken as
controls. The initial goal of comparison subject selection was
to obtain two interviews of eligible controls for each
interviewed case. For the 71 cases who were alive at the time
of the study and who were interviewed, direct interviews
were sought for their matched controls. Twenty-four cases
had died before interviews were attempted. Data were
obtained for these women from the medical record, and data
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for these women's controls were also sought from the
medical record only. Of the 380 comparison subjects
identified from computer files, 196 were no longer members
of the plan, and thus were not eligible for inclusion. Lack of
eligible controls for 13 cases necessitated the identification of
a further 13 candidates, all of whom were eligible. There
were thus 197 (380-196+13) eligible control candidates. A
letter was sent to the physicians of all cases and controls
asking permission to contact their patients for an interview.
If permission was received, a letter was sent to each woman
describing the study and notifying her that she would receive
a phone call from a study interviewer, at which time she
could refuse the interview if she so desired. Of the group of
eligible control women, 136 (69%) were included. One
hundred and twelve controls were interviewed by telephone;
data were abstracted from the medical record only for the 24
who were not included in the study, 27 could not be found;
for nine, personal contact or record interview was refused by
the patient or the physician, and two did not speak English.
Interviews were not attempted for 23 eligible controls
because data had been obtained already from sufficient
numbers of controls in the matched set. For each case, the
controls were selected for interview in the order that they
occurred on the matching list. Because interviews were
initially sought and scheduled for as many controls as
possible, there were in some instances as many as four
controls obtained for a single case. Most cases, however, had
only one matched control.
Information obtained at the time of interview for cases
and controls included details of oral contraceptive and other
drug use, menstrual history, family history, history of prior
breast lumps, education, race, weight, height, parity and age
at first pregnancy (defined as any pregnancy of five or more
months' duration). For those responses that might vary with
time, cases were interviewed specifically with reference to
their date of diagnosis. The reference date for each control
was the diagnosis date of the matched case. Record
abstractions were similarly keyed to date of diagnosis or to a
corresponding reference date.
Information about oral contraceptive use (including dates
of use and brands used) obtained during interview was,
whenever possible, verified using medical records if the
woman was uncertain about details of her oral contraceptive
history. About 60% of women provided details of their oral
contraceptive histories which were considered reliable. For
the remaining 40% of women, details of oral contraceptive
history were obtained for about two-thirds, either from
Group Health medical records, or from prior health care
providers.
In addition to the 95 cases occurring from July 1978 to 31
December 1983 and their 136 matched controls, we also
analysed information from an earlier study (Jick et al., 1980)
covering the period 1 July 1975 to 30 June 1978. The early
study used the same interview forms and procedures.
Controls were women hospitalised for conditions thought
not to be associated with oral contraceptive use. Corro-
borative information on oral contraceptive use reported in
the interview was not obtained in this earlier study. The
combined total of cases and controls from the two studies
was 127 and 174 respectively for a ratio of one case to 1.4
controls.
Analyses were carried out using multiple logistic regression
techniques to control for potential confounding variables
(Breslow & Day, 1980). Estimates of the ratio of the rate of
breast cancer in exposed groups to the rate in otherwise
similar non-exposed groups were drawn from the coefficients
of the logistic regressions. All models included categorical
terms for exposures under study, for information source
(interview plus records or medical records alone) (Walker et
al., 1988) and for the matching variables: year of birth, year
of diagnosis and first digit of the medical history number.
Tests for trend were based on a comparison of coefficients to
their standard errors using non-categorical models.
Table I Characteristics of breast cancer cases and
controls (Group Health Cooperative of Puget
Sound, 1 July 1975 to 31 December 1983)
Case (%) Control (%)
Year of diagnosis
1975 (July to Dec.)
1976
1977
1978
1979
1980
1981
1982
1983
Total
Age at case diagnosis
.29
30-34
35-39
40-42
Total
Age at menarche
<11
11-12
13-14
15+
Unknown
Total
Age at first pregnancy
None
<20
20-23
24-27
28 +
Unknown
Total
4 (3)
8 (6)
8 (6)
16 (12)
17 (13)
12 (9)
21 (17)
26 (20)
15 (12)
127
9 (7)
20 (16)
68 (53)
30 (24)
127
11(9)
47 (37)
41 (32)
9 (7)
19 (15)
127
36 (28)
16 (13)
26 (20)
23 (18)
15 (12)
11(9)
127
Age at first oral contraceptive use
None 29 (23)
<21 21 (17)
21-24 29 (23)
25-28 19 (15)
29+ 16 (13)
Unknown 13 (10)
Total 127
History of maternal cancer
Yes 26 (20)
No 87 (69)
Unknown 14 (11)
Total 127
History of breast lumps
Yes
No
Unknown
Total 1:
Current cigarette smoking
Non-smoker
Smoker
Unknown
Total 1:
Total oral contraceptive use
Ever
Never
Unknown
Total 1
42 (33)
63 (50)
22 (17)
27
82 (65)
29 (23)
16 (13)
27
78 (61)
28 (22)
21 (17)
27
5 (3)
10 (6)
9 (5)
21 (12)
24 (14)
15 (9)
31 (18)
35 (20)
24 (14)
174
9 (5)
21 (12)
98 (56)
46 (27)
174
8 (5)
72 (41)
60 (34)
14 (8)
20 (11)
174
34 (20)
36 (21)
42 (24)
40 (23)
13 (7)
9 (5)
174
23
27
57
27
17
23
174
(13)
(16)
(33)
(16)
(10)
(13)
22 (13)
129 (74)
23 (13)
174
37 (21)
117 (67)
20 (12)
174
116 (67)
42 (24)
16 (9)
174
124 (71)
29 (17)
21 (12)
174
The reference date for controls was the date of
diagnosis of the matched case.
Results
Table I presents the distribution of selected case and control
characteristics. Nulliparity and late age of first pregnancy,
history of breast lumps, history of maternal cancer and early
age of menarche are more common among cases than
controls, in accord with previous findings (Kelsey, 1979).
There was no difference between cases and controls with
respect to smoking status. In a preliminary analysis, current620 S.S. JICK et al.
Table II Duration of ever use of oral contraceptives in
women <43 years of age for breast cancer cases and
controls at Group Health Cooperative of Puget Sound
(1975-1983)
Duration Cases Controls RR' 95% CI
Non-user 28 29 1.0 -
<5 years 36 71 0.7 (0.3, 1.7)
5-9 years 25 38 0.7 (0.3, 1.8)
>10 years 17 15 1.4 (0.4, 4.6)
Unknown 21 21 1.9 (0.6, 6.7)
aFrom a multiple logistic regression, with control for
the matching factors (see text), plus age at first pregnancy,
history of breast lumps, age of menarche and history of
maternal cancer.
Table III Duration of oral contraceptive use before first
pregnancy among women <43 years of age for breast
cancer cases and controls at Group Health Cooperative of
Puget Sound (1975-1983)
Duration Cases Controls RRa 95% CI
Non-user 48 75 1.0 -
<1 year 1 4 0.3 (0.02, 3.5)
1-3 years 15 29 0.8 (0.3, 2.0)
4 years 12 11 1.3 (0.3, 4.6)
Unknown 51 55 0.3 (0.1, 1.5)
Nulliparious women are not included in this analysis.
aFrom a multiple logistic regression, with control for
the matching factors (see text), plus age at first pregnancy,
history of breast lumps, age of menarche and history of
maternal cancer.
Table IV Type of oral contraceptive used before first pregnancy
among women <43 years of age for breast cancer cases and
controls at Group Health Cooperative of Puget Sound (1975-1983)
Type of
oral contraceptive Cases Controls RR' 95% CI
Non-user 48 75 1.0 -
Mestranol 17 25 0.9 (0.3, 2.3)
Ethinyl oestradiol 5 5 1.7 (0.3, 8.0)
Unknown 21 35 0.4 (0.2, 1.3)
Nulliparious women were not included in this analysis.
aFrom a multiple logistic regression, with control for the matching
factors (see text), plus age at first pregnancy, history of breast
lumps, age of menarche and history of maternal cancer.
Table V Relation between breast cancer and multiple
risk factors among women <43 years of age at Group
Health Cooperative of Puget Sound (1975-1983)
Cases Controls RR' 95% CI
Age at menarche
<11 yearsb 11 8 1.0 -
11-12 years 47 72 0.3 (0.1, 1.2)
13-14 years 41 60 0.4 (0.1, 1.3)
>15 years 9 14 0.3 (0.1, 1.5)
Unknown 19 20 0.3 (0.1, 2.1)
Age at first pregnancyc
<20 yearsb 16 36 1.0 -
20-23 years 26 42 1.8 (0.7, 4.3)
24-27 years 23 40 1.4 (0.6, 3.4)
28 years 15 13 3.7 (1.2, 10.9)
Unknown 11 9 2.7 (0.5, 14.3)
History of breast lumps
Nob 63 117 1.0 -
Yes 42 37 1.4 (0.7, 2.8)
Unknown 22 20 1.1 (0.3, 4.6)
History of maternal cancer
Nob 87 129 1.0 -
Yes 26 22 2.2 (1.0, 5.1)
Unknown 14 23 0.4 (0.1, 1.3)
aResults of a multiple logistic regression analysis
controlling for the matching variables (see text); bReference
category; cNulliparous women are not included in this
analysis.
Table VI Concordance between oral contraceptive
histories obtained by interview and automated pharmacy
files for subjects with at least 3 years of relevant
pharmacy information
Cases Controls
OC use reported OC use reported
by interview by interview
Pharmacy data Yes No Total Yes No Total
OC use ioa 2b 12 1la 6b 17
No OC use 2 27 29 0 60 60
Total 12 29 41 11 66 77
aDates of use did not agree within one year in three
cases and one control; bOne prescription present in
pharmacy file in two cases and two controls. Two to four
prescriptions present in four controls.
smoking did not materially confound the oral contraceptive-
breast cancer relationship, and it is therefore not considered
in the analyses presented below.
Use of oral contraceptives at any time was slightly less
frequent among cases than among controls. Among the 127
cases, 78 (61%) had used oral contraceptives at some time;
among the 174 controls, 124 (71%) had ever used oral
contraceptives. The rate ratio (RR) estimate for any use of
oral contraceptives compared with no use was 0.9 (95%
CI=0.4, 1.9) after controlling for age of first pregnancy,
history of breast lumps, age of menarche and history of
maternal cancer. There was no material difference found
between cases and controls with respect to total duration of
use of oral contraceptives. The RR estimates for 1-4 years,
5-9 years, 10+ years and unknown duration were 0.7, 0.7,
1.4 and 1.9 respectively, controlling for age of first
pregnancy, history of breast lumps, age of menarche and
history of maternal cancer (Table II). The estimates obtained
from the interviewed and noninterviewed subjects were,
within the limits of sampling error, substantially the same.
Use of oral contraceptives beforefirst pregnancy
The RR estimate associated with any use of oral contra-
ceptives before first pregnancy was 0.9 (95% CI=0.4, 2.1).
History of breast lumps, history of maternal cancer, age of
menarche and age at first pregnancy were all accounted for
in the logistic regression model in addition to the matching
factors including data source. Age at first pregnancy was the
strongest confounder in these data.
We also investigated duration of use before first pregnancy
as well as oestrogen formulation of the oral contraceptive
used (mestranol versus ethinyl oestradiol) before first
pregnancy. Cases and controls did not differ materially with
respect to duration of oral contraceptive use before first
pregnancy. For users of less than 1 year, 1-3 years, 4 or
more years and unknown duration before first pregnancy the
RR estimates were 0.3, 0.8, 1.3 and 0.3 respectively (Table
III). A test for trend over the three levels of known use was
not significant (P=0.2). Likewise, there was no material
difference in oestrogen formulation of the pill used. The RR
estimate for mestranol, ethinyl oestradiol and unknown
formulation of oral contraceptive, as compared to non-use of
any oral contraceptive, were 0.9, 1.7 and 0.4 respectively
(Table IV).
Although oral contraceptive use before first pregnancy was
not associated with breast cancer risk, a number of other
characteristics were. Table V presents the relation between
breast cancer, age at menarche and age at first pregnancy,
history of breast lumps and history of maternal cancer
obtained from a multiple logistic regression from which
terms related to oral contraceptive use has been deleted. As
suggested by the crude data in Table I, age at menarche, age
at first pregnancy, maternal history of breast cancer and
history of breast lumps were all associated with breast
cancer to extents similar to those that have been previously
reported in premenopausal women.ORAL CONTRACEPTIVES AND BREAST CANCER 621
In order to evaluate the validity of the histories of most
recent oral contraceptive use reported at interview, we
compared these histories with information available from the
automated pharmacy (which was activated in July 1975) for
cases and controls who had at least 3 years of pharmacy
experience recorded before the index date (Table VI).
Concordance was substantial and similar for both cases and
controls and for those reporting oral contraceptive use and
non-use during the relevant period.
Discussion
The present study of 127 women with breast cancer below
age 43 years and of matched controls showed no association
with oral contraceptive use before a first full term pregnancy
(RR=O.9, 95% upper confidence bound=2.1). The RR
estimate for use of oral contraceptives for 4 or more years
before a first pregnancy was 1.3 by comparison to non-use
of oral contraceptives (95% upper confidence bound=4.6).
No material association between past use of oral contra-
ceptives at any time and breast cancer was present.
The study yielded results for other breast cancer risk
factors which are consistent with those often found by
others. Women with breast cancer were more likely to be
nulliparous, to have a later age of first pregnancy, an earlier
age of menarche, a family history of breast cancer and a
history of breast lumps than were controls.
As recently reviewed by Skegg (1988), the results of case-
control studies of breast cancer may be distorted by a
number of potential biases involving, most importantly,
selection of cases and controls and information on past use
of oral contraceptives. The current study was carried out
with knowledge of all cases of breast cancer that had
occurred in a defined population; only a few women were
not included in the analysis. Thus case selection bias is
unlikely to be important. Control subjects were selected at
random either from a membership roster that included all
the base population or from hospitalisation lists that
captured all hospitalisations in the base population. Details
of past oral contraceptive use derived from patient interviews
were often confirmed and amplified by review of clinical
charts. This would tend to mitigate both recall bias and
recall error.
We were able to obtain information on the concordance
between histories of recent oral contraceptive use obtained
by interview and the information present on automated
pharmacy files which were initiated at GHC in July 1975
(Table VI). The small amount of discordance (<10%) was
due in considerable degree to the presence of a single listed
prescription for oral contraceptives among women who did
not report use during the corresponding time period. These
findings provide reassurance that oral contraceptive histories
obtained at interview were reasonably accurate, and accurate
to the same degree in cases and controls.
Previously published studies that examined the use of oral
contraceptives before first pregnancy have yielded conflicting
results. The studies of McPherson et al. (1987) and Meirik
et al. (1986) concluded that there was a positive association
between use of oral contraceptives before a first pregnancy
and breast cancer, although their findings on the effect of
duration of use were quite different. Pike et al. (1981) found
a positive association as well but a later analysis (Pike et al.,
1983) suggested that the association was explained by con-
founding by use before age 25. The studies of the American
Cancer and Steroid Hormone (CASH) Study (1986) and
those of Rosenberg et al. (1984) and Paul et al. (1986) were
generally reported as negative. The CASH breast cancer data
have recently been further reviewed by Schlesselman et al.
(1988) in an effort specifically to identify risks associated
with a long interval since first oral contraceptive use. No
excess risk was found. The current study provides further
evidence against a positive association between oral contra-
ceptive use before a first pregnancy and the risk of breast
cancer. While no study can yet address the risk more than 20
years following first use of oral contraceptives, this and
other studies provide reassuring information of risk in the
experience to date.
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